ProductLife Group Kicks off Autumn Event Programme With Regulatory Information Management Webinar on IDMP
![](/46/pdcnewsitem/03/36/61/e1gnSpB7Vzie5gd.png)
Life sciences outsourcing and consulting services specialist ProductLife Group (PLG) has announced that the first event of its PLG Evolve autumn programme will focus on identification of medicinal products (IDMP) compliance.
The Webinar, “Taking a Strategic Approach to the Implementation of the IDMP,” to take place at 14:00 Central European Time on 18 September 2014, will be led by life sciences industry heavyweights who will discuss the challenges pharmaceutical and medical device suppliers face as they prepare to comply with new requirements around medicinal product information submission in time for a European Union deadline of 1 July 2016. By that date, affected companies will have to meet the new IDMP global standards of the International Organization for Standardization.
With less than 2 years to go to get product data in order, consultant Andrew Marr, an expert on the requirements stipulated by the latest product information standards, will copresent this timely session alongside Joerg Steuben, a Boehringer Ingelheim senior expert on quality and regulatory processes and documentation. The two will be joined by Sophie Daniel, head of quality, process, and information management at ProductLife Group.
Points of discussion will include
• The scope of IDMP from both regulatory and broader health-care perspectives
• The steps involved in bringing IDMP to fruition, including the development of IDMP implementation guides
• Assessment and monitoring of regulatory developments in the lead-up to IDMP
• What IDMP means for companies and how to achieve an effective and compliant transition from the latest eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) standard to IDMP, its successor.
Originally designed to aid in identification of substances and medicines for pharmacovigilance purposes, IDMP has evolved into something much broader and deeper than its XEVMPD predecessor. There is also growing interest in using IDMP data for broader health-care purposes; for example, to support medical history provision for patients being treated in other countries.
In announcing the opening event, PLG Chairman and CEO Pierre Cuny said: “We felt it was important to start our autumn schedule with a subject that will resonate with organisations right across our industry. Preparing for comprehensive product data compliance is no easy feat, especially now that the scope is so broad. Our speakers will be advocating a strategic, well-thought-out approach that creates maximum opportunity for companies to both satisfy regulatory requirements and deliver something beneficial for their businesses.”
Related News
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance